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Racotumomab is a murine anti-idiotype cancer vaccine targeting NeuGcGM3 on
melanoma, breast, and lung cancer. In order to characterize the immunogenicity of
alum-adsorbed racotumomab in a non-clinical setting, Leghorn chickens were immunized
in dose levels ranging from 25µg to 1600µg. Racotumomab was administered
subcutaneously in the birds’ neck with three identical boosters and serum samples
were collected before, during and after the immunization schedule. A strong antibody
response was obtained across the evaluated dose range, confirming the immunogenicity
of racotumomab even at dose levels as low as 25µg. As previously observed when
using Freund’s adjuvant, alum-adsorbed racotumomab induced an idiotype-specific
response in all the immunized birds and ganglioside-specific antibodies in 60–100%
of the animals. In contrast to the rapid induction anti-idiotype response, detection of
ganglioside-specific antibodies in responsive animals may require repeated boosting.
Kinetics of anti-NeuGcGM3 antibody titers showed a slight decline 2 weeks after
each booster, arguing in favor of repeated immunizations in order to maintain antibody
titer. Interestingly, the intensity of the anti-NeuGcGM3 response paralleled that of
anti-mucin antibodies and anti-tumor antibodies, suggesting that the in vitro detection of
anti-ganglioside antibodies might be a surrogate for an in vivo activity of racotumomab.
Taken together, these results suggest that Leghorn chicken immunization might become
the means to test the biological activity of racotumomab intended for clinical use.
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INTRODUCTION
Racotumomab is a murine IgG1 monoclonal antibody targeting
NeuGcGM3, a tumor associated antigen in human melanoma
(Alfonso et al., 2002), breast cancer (Diaz et al., 2003; Guthmann
et al., 2006), lung cancer (Neninger et al., 2007; Hernandez et al.,
2011), as well as several pediatric tumors of such as neurob-
lastoma, retinoblastoma, Wilm’s tumor, and Ewing’s sarcoma
(Scursoni et al., 2010, 2011). Racotumomab is an anti-idiotype
antibody to P3, an IgMmAb raised against NeuGcGM3 (Vazquez
et al., 2000). Racotumomab binds to the antigen-binding domain
on P3, but detailed analysis showed that the P3 groove that
interacts with the ganglioside’s sialic acid is not involved in
the interaction with racotumomab. Molecular modeling studies
argue against a structural mimicry by the anti-idiotype antibody
(Talavera et al., 2009). Rather, it is hypothesized that immuniza-
tion with racotumomab induces P3-like antibodies with con-
served VH germline sequences that confer them the ability to bind
to NeuGcGM3, just as P3 (Boffey et al., 2005).
The immunogenic properties of racotumomab emulsified
with Freund’s adjuvant have been previously studied in Leghorn
chickens (Hernandez et al., 2005). Results were reported for a
unique 0.1mg dose level. Racotumomab was shown to be highly
immunogenic, with a marked immune dominance of racotu-
momab idiotype. In addition to anti-racotumomab antibod-
ies, immunized chickens produced anti-NeuGcGM3 antibodies
(Hernandez et al., 2005). As is the case in humans, NeuGcGM3
is a heterophilic antigen in chickens, which render this ganglio-
side a species of choice to study the immunological properties of
racotumomab for clinical applications.
Racotumomab has been administered to melanoma, breast,
and lung cancer patients adsorbed to aluminum hydroxide
(alum). In this report we discuss the results of immunization
of chickens with the same alum-adsorbed formulation used in
clinical trials with cancer patients. We investigated the dose-
dependence over a 25–1600µg dose range and the booster
requirements for a maximal response. We further pursued the
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specificity of the antibody response to a glycolylated mucin and
to a NeuGcGM3-expressing tumor cell line.
MATERIALS AND METHODS
EXPERIMENTAL DESIGN
Six to eight week-old leghorn chickens bred under SPF con-
ditions were immunized subcutaneously behind the neck with
25–1600µg of 1mg/ml alum-adsorbed racotumomab on days
0, 7, and 21. 1600µg doses were administered by means of
two 800µl injections. 25 and 75µg doses were administered
by previously diluting the immunogen 1:10 in sterile sodium
saline (immediately prior to injection) to administer 250 and
750µl, respectively. Injections were performed with an Accura
865 microdispenser pipette (Socorex, Ecublens, Switzerland) fit-
ted with a 25G needle.
1.0ml blood samples were drawn at baseline and at days
14, 21, 28, and 35 from the wing vein with a 21G needle fitted
to a 5ml syringe. The blood was allowed to clot in the syringe
and the serum was recovered, centrifuged and stored at −20◦C
till analyzed.
ENZYME LINKED IMMUNE SORBENT ASSAYS
Anti-racotumomab antibodies were determined by ELISA. Costar
3590 microtiter plates (Costar, Cambridge, MA) were sensitized
with 10µg/ml racotumomab or with the isotype-matched anti-
body iorC5 (Center of Molecular Immunology, Havana, Cuba).
Serum samples were used diluted 1:10000. Bound IgG antibodies
were detected with an alkaline phosphatase-conjugated goat anti-
chicken IgY (Sigma Chemical Co., Saint Louis, MO) followed by
1mg/ml p-nitrophenyl phosphate in diethanolamine buffer.
Anti-NeuGcGM3 antibodies were determined by ELISA
using NeuGcGM3-coated (20 ng/well in HPLC grade methanol)
PolySorp microtiter plates (Nunc, Rochester, NY). Control wells
were coated with N-acetyl GM3 (Enzo Life Sciences, Miami, FL).
After methanol evaporation for 2 h under vacuum, plates were
blocked with 1% bovine serum albumin (cat. # A3803; Sigma
Chemical Co.) in PBS. Serum samples were used either at a 1:100
dilution (for kinetics analysis) or in a two-fold dilution series
starting 1:100 (for titration). Bound antibodies were detected as
described above. Absorbance in control wells was subtracted to
yield the specific anti-NeuGcGM3 reactivity. Titers were defined
as the inverse of the dilution yielding an absorbance of 0.1 and
obtained by interpolation in absorbance vs. 1/dilution plots.
Anti-mucin antibodies were determined by ELISA using
Costar 3590 microtiter plates coated with bovine NeuGc rich
mucin (500µg/ml; cat. # M3895; Sigma Chemical Co.). Serum
samples were used at a 1:100 dilution. Bound antibodies were
detected with alkaline phosphatase-conjugated goat anti-chicken
IgY (Sigma Chemical Co.) as described above.
Chickens were considered to elicit a positive antibody response
if post-vaccination samples had an absorbance at least twice the
value of baseline samples and superior to 0.25 arbitrary units.
FLOW CYTOMETRY
P3X63 Ag8 653 murine myeloma cells were incubated (2 × 105
per tube) with 20µl sample sera. After washing, bound anti-
bodies were detected with an FITC-conjugated goat anti-chicken
IgY (Sigma Chemical Co.) and analyzed with a FACScalibur
cytometer (Becton-Dickinson, Franklin Lakes, NJ). Patients were
considered responsive when two post-vaccination samples had
a two-fold increase in fluorescence intensity with respect to
baseline.
IMMUNOHISTOCHEMISTRY
Five-µm tumor sections from formalin-fixed, paraffin-embedded
human non-small cell lung carcinoma (NSCLC) samples were
processed using the usual paraffin technique. Slides were incu-
bated for 30min with immunized and non-immunized serum
samples (1:100 in PBS) and then with biotinylated goat anti-
chicken IgY (Abcam, Cambridge, MA) for 30min, followed
by peroxidase-conjugated avidin–biotin complex for 1 h. Bound
antibodies were detected by incubation with diaminobenzidine
substrate and tumor sections were then counterstained with
haematoxylin. Pertinent specificity tests were performed, includ-
ing blocking of endogenous peroxidase and use of an isotype-
matched negative control antibody.
STATISTICAL ANALYSIS
Data from time-course experiments of antibody induction are
shown as mean absorbances for each time point, where the
amount of animals in each experiment is indicated in the legend
to each figure. Error bars represent the standard deviation. When
indicated, results are shown for representative animals, and no
error bars are shown. The coefficient of variation for duplicate
ELISA wells was<5%.
Maximal antibody titers are presented in scatter plots, and the
amount of animals in each group is indicated in the legend. The
titer median is indicated with a horizontal bar.
Anti-NeuGcGM3 and anti-mucin antibody responses in indi-
vidual samples were compared in X–Y plots where the X value
depicts the anti-mucin absorbance and the Y value depicts the
anti-NeuGcGM3 absorbance. The Spearman test was used to
assess correlation. The Spearman correlation coefficient is indi-
cated, with the corresponding P value (indicating the chance that
random sampling would result in a correlation coefficient as far
from zero as observed).
RESULTS
KINETICS OF RACOTUMOMAB-INDUCED ANTIBODY RESPONSE
Chicken were immunized with 200µg of alum-adsorbed raco-
tumomab at day 0, and boosted at days 7 and 21. Blood was
drawn at baseline, days 14, 21, 28, and 35 to assess the antibody
response. All chickens presented racotumomab-specific antibod-
ies after immunization. Antibody levels peaked after two doses
(day 14) and remained at the same level after an additional boost.
Antibody levels decayed after the first week following each boost,
and repeated boosting was required to maintain the antibody
levels (Figure 1). Maximal antibody levels were most frequently
observed 7 days after the previous immunization (in 65% of
birds) than in time points 14 days after the immediately previous
boost (the remaining 35% of birds).
Anti-ganglioside levels, in contrast, presented a very high vari-
ability in the antibody values (Figure 2A) as a consequence of
a heterogeneous kinetics in antibody response. Whereas some
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birds showed an early response with a maximal response after two
doses and a gradual reduction thereafter (Figure 2B), other birds
showed an induction of significant antibody levels only 2 weeks
after the last immunization (Figure 2C).
FIGURE 1 | Time course of the induction of anti-racotumomab
antibodies. Chickens (n = 10) were immunized with 200µg alum-adsorbed
racotumomab (arrows) and the induction of anti-racotumomab antibodies
was assessed at the indicated times. The mean absorbance and standard
deviation is shown.
DOSE DEPENDENCE OF ANTIBODY RESPONSE
Six cohorts of 10 chickens each received the immunization sched-
ule described above in a dose level ranging from 25 to 1600µg
alum-adsorbed racotumomab. Serum samples were analyzed for
anti-racotumomab and anti-ganglioside response. All chickens
elicited anti-racotumomab antibodies in entire dose level range
studied. The proportion of chickens that induced anti-ganglioside
antibodies was dose dependent, with 100% responsive birds at
the 200µg dose level. The groups receiving the lowest and high-
est dose levels presented a lower proportion of chickens with
ganglioside-specific responses (80% and 60%, respectively).
The maximal antibody response for each bird was recorded
for dose-response correlation. No difference was found in the
anti-racotumomab response in the 25–200µg immunogen range.
Interestingly, higher dose levels (800–1600µg) yielded a slightly
weaker anti-racotumomab antibody response (Figure 3A).
The anti-ganglioside response, in contrast, showed a maxi-
mal response in the 200–400µg dose range and a comparatively
weaker response in both the lower and higher ends of the exam-
ined dose range. In the latter groups, the titer mean was lower
and the fraction of birds who failed to show detectable anti-
ganglioside antibodies was increased (Figure 3B).
IMMUNODOMINANCE OF RACOTUMOMAB IDIOTYPE
The influence of dose-level on the immunodominance of raco-
tumomab idiotype was assessed by comparatively determining
the binding to racotumomab and to a control isotype-matched
FIGURE 2 | Time course of the induction of anti-NeuGcGM3 antibodies.
(A) Chickens (n = 10) were immunized with 200µg alum-adsorbed
racotumomab (arrows) and the induction of anti-NeuGcGM3 antibodies was
assessed at the indicated times. The mean absorbance and standard deviation
is shown. (B and C) Time course of the induction of anti-NeuGcGM3 antibodies
in individual chickens immunized with 200µg alum-adsorbed racotumomab
(arrows). The induction of anti-NeuGcGM3 antibodies is indicated for a
representative early responder (B) and a representative late responder (C).
www.frontiersin.org January 2013 | Volume 3 | Article 422 | 3
Guthmann et al. Anti-ganglioside response to racotumomab immunization
FIGURE 3 | Dose dependency of the antibody response. Ten chickens
in each dose level group were immunized as described. Sera were
analyzed for anti-racotumomab and anti-NeuGcGM3 antibodies. Maximal
absorbance (anti-racotumomab) or titer (anti-NeuGcGM3) were recorded
for each chicken and used for comparison between dose levels. (A)
Maximal anti-racotumomab antibodies for individual chickens receiving the
indicated dose (mean absorbance is indicated with a bar). (B) Maximal
anti-NeuGcGM3 antibody titers for individual chickens receiving the
indicated dose (median titer is indicated with a bar).
monoclonal antibody (iorC5). Reactivity against racotumomab
was approximately twice than that to the isotype control at all
time points, confirming that a substantial proportion of the
elicited antibodies are directed toward the racotumomab idio-
type and that this proportion does not vary significantly with
re-immunization (Figure 4).
The anti-idiotype response (the difference of reactivity of
serum antibodies to racotumomab and to isotype control) was
compared throughout the 200–1600µg dose level range and was
found to closely parallel that of the anti-racotumomab response
and decreased at the higher dose level (not shown).
SPECIFICITY OF ANTI-GANGLIOSIDE RESPONSE
The fine specificity of the elicited anti-carbohydrate antibod-
ies was assessed by determining their reactivity against N-Acetyl
GM3 (a widely expressed ganglioside in the surface of normal
cells), against an N-glycolyl neuraminic acid-rich mucin, against
a tumor cell line expressing high levels of NeuGcGM3 on its
cell surface and against NeuGcGM3-positive non-small cell lung
cancer (NSCLC) tissue sections.
FIGURE 4 | Induction of anti-idiotype antibodies. Time course of
anti-racotumomab and anti-iorC5 (an isotype-matched control antibody)
antibodies in a representative chicken in the 200µg dose level group
(N = 10). Immunization time line is represented by arrows. Similar
immunodominance of racotumomab idiotype was observed in all other
dose levels. The dashed line depicts the time course of anti-idiotype
antibodies (Absanti-racotumomab–Absanti-iorC5).
Although NeuGcGM3 and N-acetyl GM3 only differ by a sin-
gle oxygen atom on the acetyl group on the amine at carbon 5 of
the sialic acid, no N-acetyl GM3-specific antibodies were detected
irrespective of the number of immunizations or the kinetics of
anti-ganglioside response (Figure 5A).
Serum antibodies were also reactive against mucin, suggest-
ing that sialic-acid reactivity may be maintained when the latter
is present on a different molecular backbone, as is the case
with Neu5Gc-rich mucin. Furthermore, the intensity of reactiv-
ity against mucin paralleled that against NeuGcGM3 (Figure 5B),
arguing for a relationship between both specificities. However,
whether this is the consequence of cross-reaction or epitope
spreading remains to be determined.
Reactivity of serum antibodies against NeuGcGM3 was
also paralleled by reactivity against the NeuGcGM3-expressing
murine myeloma line X-63. Whereas serum of non-responsive
chicken failed to stain the X-63 cells (not shown), sera reac-
tive against NeuGcGM3 (as assessed by ELISA) also recognized
NeuGcGM3 exposed on the cell surface (Figure 5C).
NeuGcGM3 has been described as a tumor antigen for
NSCLC in humans (van Cruijsen et al., 2009; Blanco et al.,
2012). Considering this, we assessed the presence, in baseline
and post-vaccination serum samples, of antibodies reacting with
NeuGGM3 on fixed and processed NSCLC tissue sections. As it
is shown in Figure 5D, the post-vaccination serum (but not the
baseline serum) was able to react with tumor sections showing a
moderate to intense immunoreactivity.
DISCUSSION
Water in oil emulsions are very effective vaccine vehicles for
improving antigen-specific humoral responses in chickens, owing
to a combination of antigen residence-prolonging activity and
direct immune stimulation (Jansen et al., 2007). Hernandez and
co-workers have previously used Freund’s adjuvant to emulsify
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100µg doses of racotumomab for immunization of Leghorn
chickens (Hernandez et al., 2005). Four intramuscular injections
at 2 weeks interval elicited high titer anti-racotumomab anti-
bodies with immunodominance for its idiotype. In addition,
anti-ganglioside antibodies were also induced, with specificity
for NeuGcGM3 and NeuGcGM2 but not for NeuAcGM3 and
NeuAcGM2, suggesting the activation of an anti-idiotypic cascade
leading to a glycolylated sialic acid-specific antibody response
(Hernandez et al., 2005).
However, emulsions are seldom used in the clinical set-
ting, due to a comparatively increased toxicity. A few can-
cer vaccines have been combined with oil adjuvants (i.e.,
Montanide) or saponins (i.e., QS-21) in the need to maxi-
mize immune response in immunocompromised patients (Mesa
and Fernandez, 2004). Adsorption to aluminum-based salts, on
the other hand, is the most common commercial adjuvant to
date, and enhances Th2 responses and antibody production
(Mesa and Fernandez, 2004). Alum-adsorbed racotumomab has
been extensively tested as a cancer vaccine and is presently
undergoing a phase III clinical trial (ClinicalTrials.gov identifier:
NCT01460472).
Because alum is less effective than microbial-derived adjuvants
such as CpG ODN (de Paula et al., 2011) or Freund’s adjuvant
(Mayo et al., 2005; Berezin et al., 2010), we investigated the
immune response to alum-adsorbed racotumomab in Leghorn
chickens.
Antigen dosage is effective in poultry immunization in the
20µg-range (Fassbinder-Orth et al., 2009). We have examined
dose levels ranging from 25 to 1600µg of alum-adsorbed racotu-
momab, and described a sustained anti-racotumomab response
down to 25µg of immunogen, supporting the strong immuno-
genicity of the racotumomab idiotype.
Maximal anti-ganglioside response was observed in the
200–400µg range, where a responsiveness of 100% is observed
and the average antibody titer reaches its peak. However, anti-
NeuGcGM3 antibodies were also elicited with a dose level as low
as 25µg. The decline of the anti-ganglioside response at immuno-
gen dose-levels in excess of 800µg parallels that of the anti-
racotumomab response, suggesting that overdosingmight equally
hinder both responses and that anti-racotumomab response can
only be obtained at an optimal immunogen dose.
Whereas, the anti-racotumomab response is characterized
most chickens by an early response followed by a sustained anti-
body production, the anti-ganglioside response includes both
early-responders in which the titer peak after two administra-
tions and decline thereafter, and late responders which have
FIGURE 5 | Specificity of racotumomab-induced antibody response.
(A) Anti-ganglioside response. The time course of anti-NeuGcGM3 and
anti-NeuAcGM3 antibody response is shown for a chicken immunized with
200µg racotumomab as previously described (one chicken is shown,
representative of 10). Similar results were obtained with all dose levels, with
no induction of anti-NeuAcGM3 antibodies (not shown). (B) Anti-mucin
response. Serum samples of different anti-NeuGcGM3 antibody content and
from different dose level groups (n = 26) were tested for anti-mucin antibodies
and the absorbencies for each sample was added to an x–y plot (Spearman
r = 0.66; p < 0.001). (C) Anti-NeuGcGM3+ cell line antibodies. X-63 myeloma
cells were incubated with serum samples and stained for cell-binding IgY
antibodies. Overlaid histograms are shown for three samples of a chicken
from the 200µg dose level group. Filled histogram: baseline serum sample.
Dotted line: day 14 serum sample. Solid line: day 28 serum sample.
(D) Anti-NeuGcGM3 positive tumors response. NSCLC tumor section were
incubated with baseline (left panel) and post-immunization (right panel) serum
samples and stained for bound IgY antibodies. Serum of one chicken from the
400µg dose level group was used. Original magnification X100, X1000 (insets).
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undetectable anti-ganglioside antibodies before the third admin-
istration. Heterogeneous kinetics in ganglioside-specific antibody
response has previously been described by us in breast can-
cer patients receiving 16 racotumomab injections over a 50-
week period (Guthmann et al., 2006). Although some patients
developed anti-NeuGcGM3 IgG responses after 4 doses, late
responders required up to 13 doses to elicit anti-ganglioside
IgG antibodies. All patients eventually developed anti-ganglioside
responses (either IgM or IgG), but the heterogeneity in the timing
of the response gave ground to the acceptance of extended vacci-
nation regimens for ensuing clinical studies. It is noteworthy that
in spite of the heterogeneity in the response time frame observed
in chickens, all the birds receiving the 200µg dose responded after
only three doses.
The immunodominance of the racotumomab idiotype was
maintained throughout the studied dose range and the decline
of the anti-idiotype response at the highest dose level (1600µg)
paralleled that of the whole anti-racotumomab response. On the
other side, consistent with previous findings by Hernandez and
co-workers, racotumomab immunization failed to induce anti-
NeuAcGM3 antibodies (Hernandez et al., 2005) in all the studied
dose range. Taken together, the results suggest that the specificity
of the immune response is note affected by dose level.
The anti-NeuGcGM3 response quantitatively paralleled that
against a NeuGc rich mucin, suggesting that the response elicited
in chicken is most probably directed against the glycolylated
sialic acid and that the chicken antibodies may bind this anti-
gen on different molecular backbones. Most interestingly, post-
vaccination sera are also able to specifically stain both the murine
NeuGcGM3-expressing X-63 cell line and NeuGcGM3-positive
human NSCLC tissue sections. Whether the chicken’s anti-
NeuGcGM3 antibodies promote oncotic necrosis of cancer cells,
as described for cancer patients treated with racotumomab
(Hernandez et al., 2011) remains to be established.
There is an increasing demand for the assessment of the bio-
logical activity of products with clinical application. The supervi-
sion of the manufacturing and product testing of cancer vaccines
falls in the US under the scrutiny of the Center for Biologics
Evaluation and Research (CBER) of the US Food and Drug
Administration (FDA). Through its Guidelines for the Industry,
the FDA frequently updates its policies regarding clinical eval-
uation (FDA, 2011). Likewise, the European Medicines Agency,
through its Committee for medicinal products for human use
(CHMP) has issued guidelines on adjuvants in vaccines (EMA,
2005). Although not directly targeted to cancer vaccines, these
regulations are expected to be applicable to quality and non-
clinical aspects of therapeutic vaccines such as anti-idiotypic
vaccines (Chabicovsky and Ryle, 2006).
The results reported herein show that treatment of Leghorn
chickens with alum-adsorbed racotumomab elicited a similar
pattern of idiotype dominance and anti-ganglioside response as
cancer patients under racotumomab immunotherapy trials (Diaz
et al., 2003; Guthmann et al., 2006). Leghorn chicken immu-
nization might therefore develop into a validated method to
assess racotumomab vaccine potency, to comparatively charac-
terize ascites- and bioreactor-derived racotumomab (Machado
et al., 2011) and to certify batch-to-batch consistency in the
manufacture of racotumomab intended for clinical use.
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